AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05840536
Drug: Furosemide plus Chlorothiazide
RxNorm normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs.
Trial: NCT00551603
Drug: continuation (darbepoetinum)
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuation of the previous darbepoetinum administration schedule
Trial: NCT01831674
Drug: GLUCOPHAGE®XR tablet 750 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLUCOPHAGE®XR 750 mg once a day
Trial: NCT04616222
Drug: CELSIOR® group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
Trial: NCT04616222
Drug: Saint-Thomas group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
Trial: NCT04751188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet every 12 hours for six months.
Trial: NCT01270438
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01270438
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01270438
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01270438
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00856193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
Trial: NCT00518271
Drug: Rapamune® (Sirolimus)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518271
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative
Trial: NCT01673620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet administered once daily
Trial: NCT04397562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02522325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will contain only cornstarch.
Trial: NCT04500886
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
Trial: NCT03458650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets
Trial: NCT03885661
Drug: Icosapent Ethyl 1000 MG [Vascepa]
RxNorm normalized name: icosapent ethyl 1000 MG [Vascepa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
Trial: NCT00003476
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT01883869
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01984736
Drug: Experimental: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00696436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, orally, once daily for up to six weeks.
Trial: NCT00944216
Drug: Salkera Emollient Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of the Salkera emollient foam twice a day during the 12 week study period.
Trial: NCT03943446
Drug: TAK-018 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-018 placebo-matching tablets.
Trial: NCT03200093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ora-Sweet 5mL taken by mouth once daily.
Trial: NCT02467023
Drug: Muscle Biopsy Medication: Versed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
Trial: NCT02467023
Drug: Muscle Biopsy Medication: Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
Trial: NCT03652051
Drug: AZR-MD-001 Mid Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZR-MD-001 is an ophthalmic ointment
Trial: NCT03652051
Drug: AZR-MD-001 Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZR-MD-001 is a vehicle ophthalmic ointment
Trial: NCT01823770
Drug: Placebo patchs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
Trial: NCT01972854
Drug: placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0% riboflavin ophthalmic solution
Trial: NCT02008773
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules 6/day oral for 16 weeks
Trial: NCT02374567
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02374567
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02374567
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00794690
Drug: Cimicifuga racemosa extract for the group
RxNorm normalized name: Cimicifuga racemosa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of Cimicifuga racemosa extract daily dor 12 months
Trial: NCT04712357
Drug: Vitamin C 500 MG Oral Tablet
RxNorm normalized name: vitamin C 500 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 MG per day for 10 days
Trial: NCT02374567
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02166268
Drug: AVANZ Phleum pratense 15,000 SQ+
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02166268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04643795
Drug: MGL-3196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral dose for 6 days
Trial: NCT01566201
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water for injection
Trial: NCT04602442
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
Trial: NCT00400439
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily for 24 weeks
Trial: NCT01267942
Drug: Enhancin
RxNorm normalized name: IgA enhancing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm.
Trial: NCT03520907
Drug: Ilioinguinal/iliohypogastric Nerve Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: block will be performed under real-time ultrasound guidance
Trial: NCT01737853
Drug: Ganforti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
Trial: NCT01737853
Drug: Krytantek
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
Trial: NCT01474720
Drug: Zostavax vaccine
RxNorm normalized name: ZOSTAVAX VACCINE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
Trial: NCT03424356
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1mcg/kg for induction
Trial: NCT04680429
Drug: RP7214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single and multiple ascending doses of RP7214
Trial: NCT04680429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single and multiple ascending doses of matching placebo
Trial: NCT00527982
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg by mouth daily for a total of 12 months.
Trial: NCT00789672
Drug: levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
Trial: NCT00789672
Drug: levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
Trial: NCT00450645
Drug: low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
Trial: NCT00680797
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel
Trial: NCT00854035
Drug: MK-0431/ONO-5435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
Trial: NCT00854035
Drug: MK-0431/ONO-5435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Trial: NCT04302415
Drug: There is no other intervention, only clinical treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no other intervention, only clinical treatment.
Trial: NCT00639756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given for 2 weeks
Trial: NCT01936844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for days 1, 2, and 3
Trial: NCT01838590
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Trial: NCT00305604
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin matching placebo for up to a 24-wk treatment period.
Trial: NCT04565600
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 Mg Oral Tablet
Trial: NCT04228601
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX
Trial: NCT03400163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD
Trial: NCT02790710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03147443
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
Trial: NCT03147443
Drug: Tested drug minus heat-clearing herbs
RxNorm normalized name: Arctium minus root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
Trial: NCT00715858
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule, 100 mg, b.i.d., 12 months
Trial: NCT00715858
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matched to rifampin; placebo matched to doxycycline
Trial: NCT03489512
Drug: A (Chloraprep)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
Trial: NCT03489512
Drug: B (Clorhexidine 2%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
Trial: NCT01007721
Drug: 671800 ED placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of BI 671800 ED placebo (bid in the morning and evening)
Trial: NCT04019769
Drug: L-glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
Trial: NCT03043729
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
Trial: NCT01313208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection
Trial: NCT03615066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state
Trial: NCT03615066
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily with food
Trial: NCT00109577
Drug: MCN36 (nutritional supplement)
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nutritional supplement
Trial: NCT00109577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nutritional supplement
Trial: NCT00089947
Drug: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02034734
Drug: ASP3652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04969679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
Trial: NCT00982202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 3 tablets daily for \~18 months
Trial: NCT00520260
Drug: bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.09%, BID, 6 weeks
Trial: NCT00520260
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4%, BID, 6 weeks
Trial: NCT02461888
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT00754130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
Trial: NCT00754130
Drug: MK-0941
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
Trial: NCT00808210
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral or parenteral repeating dose
Trial: NCT00808210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT01376999
Drug: FSH-r (Follicule stimulate hormone)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
Trial: NCT01846650
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral Capecitabine tablets 2000mg qd
Trial: NCT04421209
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered with the same schedule of Propranolol tablets
Trial: NCT01192828
Drug: taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Take Taurine for 4 1/2 days, two doses per day
Trial: NCT00119496
Drug: theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral theophylline, 200mg bd
Trial: NCT00119496
Drug: inhaled beclomethasone and oral theophylline
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
Trial: NCT00820222
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
Trial: NCT03327558
Drug: Apriso 0.375G ER CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER capsule
Trial: NCT01300260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT00377364
Drug: Drug: Acetaminophen, Drug: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
Trial: NCT03903939
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuously infusion for 72 hours equal volume to Iloprost
Trial: NCT00095173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions, IV, N/A, every 4 weeks, 6 months.
Trial: NCT01424280
Drug: 1440115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
Trial: NCT01424280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo tablets
Trial: NCT02048488
Drug: TSR-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of cycles until progression or unacceptable toxicity develops.
Trial: NCT02199964
Drug: Endura, Refresh artificial tears
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over the counter therapy for dry eye, used 4 times a day
Trial: NCT01664637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
Trial: NCT00799890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-4 capsules
Trial: NCT01069705
Drug: Tobramycin inhalation powder
RxNorm normalized name: Tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.